Equity Overview
Price & Market Data
Price: $5.10
Daily Change: -$0.153 / 3.00%
Daily Range: $4.94 - $5.29
Market Cap: $322,849,856
Daily Volume: 689,599
Performance Metrics
1 Week: 0.81%
1 Month: 3.09%
3 Months: -30.07%
6 Months: 45.77%
1 Year: 192.4%
YTD: -24.01%
Company Details
Employees: 66
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.